Real-World Experience with Immunotherapy in Solid Tumors: A Single-Center Experience from Eastern India
Indian Journal of Medical and Paediatric Oncology · 01.02.2026 · 47 (01) · A01-A58
DOI: 10.1055/s-0046-1818486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 01.02.2026. Verfasst von Sagar Kanta und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims and Objectives: In the era of immuno-oncology, real-world experience with immune checkpoint inhibitors (ICIs) in solid tumors is an unmet need. We aim to report patterns of care, objective response, immune-related adverse events (irAEs), and survival outcomes in different solid tumors treated with ICIs at our center. Materials and Methods: This is a single-center retrospective chart review study at Tata Medical Center, Kolkata. Consecutive patients fulfilling eligibility criteria and treated with ICIs as a standard of care between 2020 and 2024 were analyzed. All data collected from electronic medical records of hospitals till July 2024. Histologically confirmed malignancy of solid organs treated with different ICIs (nivolumab, pembrolizumab, durvalumab, atezolizumab, and avelumab) as a standard of practice either in a neoadjuvant, adjuvant, or metastatic setting plus or minus chemotherapy or tyrosine kinase inhibitors were included.
Results
Out of 145 screened patients, 99 patients were eligible for analysis with a median age of 63 years (range 25–86), with the majority being male (81%) with advanced/metastatic (74%) diseases. Lung cancer (56.6%) with adenocarcinoma histology (39.4%) was most common. Among ICIs, the majority of the patients received pembrolizumab (45.5%) followed by nivolumab (26%) in the metastatic setting. 65% received monotherapy, and 30% had PDL1 expression >1%. These ICIs were used mainly in first-line and second-line (82%) settings with an objective response rate of 60%. irAEs was seen in 52% of patients, with the majority being grades 1 and 2. The most common grade 3 irAE was endocrine dysfunction. (8%), colitis (6%) and hematological (4%). With a median follow-up of 49 months, the median PFS of the cohort was 15 months (95% CI: 10.68–19.31) and 32 months (95% CI: 4.3–59.6), with PDL1 >1%. Median OS was 53 months (95% CI: 44.27–61.72).
Conclusion
In developing countries like India, where routine use of ICIs is a major challenge due to cost, access barrier, poor coverage of health insurance, etc., this study showed efficacy, safety, and survival outcomes of ICIs in real-world settings from eastern India. Publication History Article published online: 20 February 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Zitieren
APA
Kanta, S., Bhagwat, A., Biswas, B., Seth, S., Ganguly, S., Ghosh, J., Bhattacharjee, A., Dabkara, D., Sadhukhan, S., Dutta, K., Pal, S., & Roy, S. (2026). Real-World Experience with Immunotherapy in Solid Tumors: A Single-Center Experience from Eastern India. Indian Journal of Medical and Paediatric Oncology, 47(01), A01-A58. https://doi.org/10.1055/s-0046-1818486
Vancouver
Kanta S, Bhagwat A, Biswas B, Seth S, Ganguly S, Ghosh J, et al. Real-World Experience with Immunotherapy in Solid Tumors: A Single-Center Experience from Eastern India. Indian Journal of Medical and Paediatric Oncology. 2026;47(01):A01-A58. doi:10.1055/s-0046-1818486
BibTeX
@article{Kanta2026,
author = {Kanta, Sagar and Bhagwat, Aditya and Biswas, Bivas and Seth, Soham and Ganguly, Sandip and Ghosh, Joydeep and Bhattacharjee, Arnab and Dabkara, Deepak and Sadhukhan, Susmita and Dutta, Krishnendu and Pal, Souhita and Roy, Somnath},
title = {Real-World Experience with Immunotherapy in Solid Tumors: A Single-Center Experience from Eastern India},
journal = {Indian Journal of Medical and Paediatric Oncology},
year = {2026},
volume = {47},
number = {01},
pages = {A01--A58},
doi = {10.1055/s-0046-1818486}
}
EUVIMED